Tuesday, Dec 16, 1997
South San Francisco, Calif. -- December 16, 1997 --Genentech, Inc. (NYSE: GNE) and IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) announced that RITUXAN (Rituximab) is being shipped today to the oncology medical community. Rituxan was cleared for marketing by the U.S. Food and Drug Administration (FDA) on November 26, 1997.
IDEC discovered Rituxan and developed the product in collaboration with Genentech, F. Hoffmann-La Roche, Ltd of Switzerland and Zenyaku Kogyo Co., Ltd. of Japan. IDEC and Genentech co-promote Rituxan in the United States and have shared responsibility for product manufacture. Roche is responsible for marketing the product under the tradename MabThera in the rest of world, excluding Japan.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Eleven of the currently marketed biotechnology products stem from Genentech science. Genentech markets or promotes eight biotechnology products in the United States. The company has headquarters in South San Francisco and is traded on the New York Stock Exchange and Pacific Exchange under the symbol GNE.
IDEC Pharmaceuticals focuses on developing targeted immunotherapies for the treatment of cancer and autoimmune disease which are primarily designed to act through immune mechanisms. IDEC Pharmaceuticals is a registered U.S. trademark, and Rituxan is a U.S. trademark of IDEC, which is headquartered in San Diego, California.
# # #